Combination product
VP-102 clinical trials
Also written VP-102.
- studies test it
- 5
- open now
- 1
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the VP-102 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Verrica Pharmaceuticals Inc. (5)
Studies
Open first, then newest update. How each study uses VP-102 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)Not yet recruitingPhase 2Verrica Pharmaceuticals Inc.NCT07881952Written as VP-102
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)Active, not recruitingPhase 3Verrica Pharmaceuticals Inc.NCT07246590Written as VP-102
- Cantharidin and Occlusion in Verruca EpitheliumCompletedPhase 2Verrica Pharmaceuticals Inc.NCT03487549Written as VP-102 Cantharidin topical film forming solution
- Cantharidin Application in Molluscum Patients-1CompletedPhase 3Verrica Pharmaceuticals Inc.NCT03377790Written as VP-102 - Cantharidin, Topical Film Forming Solution
- Cantharidin Application in Molluscum PatientsCompletedPhase 3Verrica Pharmaceuticals Inc.NCT03377803Written as VP-102 - Cantharidin, Topical Film Forming Solution